Skip to content

002900.SZ

Harbin Medisan Pharmaceutical Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 9.98
+0.81%
Ask drillr

Year over year

Reported trailing growth

Revenue
-25.4%
EBITDA
—
EBIT
—
EPS
—
Free cash flow
-57.3%
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
-8.4%
EBITDA
—
EBIT
—
Net income
—
EPS
—
Free cash flow
+10.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026